Moderate To Severe Atopic Dermatitis - Pipeline Insight, 2025

This “Moderate to Severe Atopic Dermatitis - Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Moderate to Severe Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Moderate to Severe Atopic Dermatitis: Understanding

Moderate to Severe Atopic Dermatitis: Overview

Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder, typically beginning in infancy, characterized by dry skin, eczematous lesions, and lichenification. This condition is often associated with other IgE-mediated disorders such as allergic rhinitis, asthma, and food allergies. The prevalence of AD has been increasing over the past few decades, and it carries a significant morbidity burden. Moderate to severe AD is marked by recurrent flare-ups, leading to symptoms like intense itching, rashes, thickened or discolored skin, and raised bumps. For those with severe AD, nocturnal scratching can disrupt sleep and impact daily functioning, further exacerbating the condition. The emotional and psychological impact of AD is also significant, as patients often experience anxiety, depression, and social stigma due to the visible nature of their symptoms. Effective management requires a combination of skincare routines, medications, and sometimes lifestyle modifications to control flare-ups and improve quality of life.

Moderate to severe atopic dermatitis (AD) has a complex etiology involving both genetic and environmental factors that lead to abnormalities in the skin barrier and immune system. It is part of the atopic triad, which includes allergic rhinoconjunctivitis and asthma, and often follows the 'atopic march,' where symptoms develop sequentially. Genetic mutations, particularly in filaggrin, a protein crucial for skin hydration, are found in many AD patients and may also predispose them to other atopic conditions. Environmental triggers, such as food allergies (e.g., eggs, milk, peanuts) and smoking, can exacerbate symptoms, making management more challenging. These factors collectively contribute to the chronic and often debilitating nature of moderate to severe AD.

Moderate to severe atopic dermatitis is characterized by a range of distressing symptoms, including intense itching, redness (which may appear purple, brown, or ashen gray in people of color), and dry, flaky, or scaly skin. Affected skin may crack, swell, and become open or oozing, with crusting often forming on the surface. These symptoms can persist daily and are particularly severe in individuals with full-body eczema, where the entire body is affected. Additionally, people may experience flare-ups in specific areas such as the face, eyelids, lips, ears, neck, scalp, hands, arms, elbows, feet, legs, behind the knees, and ankles. The skin is often extremely sensitive, further exacerbating discomfort and impairing quality of life.

The treatment and management of moderate to severe atopic dermatitis involve a comprehensive approach, including trigger avoidance, daily skin care, anti-inflammatory therapy, and complementary modalities. Daily skin care focuses on applying emollients twice a day, ideally within three minutes of bathing, to prevent dryness. Topical steroids are the first-line treatment for acute flare-ups, while nonsteroidal agents like calcineurin inhibitors are used for sensitive areas. When topical treatments are insufficient, systemic therapies such as phototherapy or immunosuppressants like cyclosporine may be considered. A newly approved biologic therapy, dupilumab, offers targeted treatment by blocking IL-4 and IL-13 signaling. Complementary treatments like bleach baths may help reduce bacterial colonization, and probiotics during pregnancy and breastfeeding have shown promise in reducing the frequency of AD in children. Additionally, crisaborole, a topical PDE-4 inhibitor, has been approved for mild to moderate cases, further expanding treatment options.

'Moderate to Severe Atopic Dermatitis- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Moderate to Severe Atopic Dermatitis pipeline landscape is provided which includes the disease overview and Moderate to Severe Atopic Dermatitis treatment guidelines. The assessment part of the report embraces, in depth Moderate to Severe Atopic Dermatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Moderate to Severe Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Moderate to Severe Atopic Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Moderate to Severe Atopic Dermatitis.

Moderate to Severe Atopic Dermatitis Emerging Drugs Chapters

This segment of the Moderate to Severe Atopic Dermatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Moderate to Severe Atopic Dermatitis Emerging Drugs

VC005: Jiangsu vcare pharmaceutical technology co., LTD

VC005 is a new, highly potent, and highly selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. The drug selectively inhibits JAK1 to reduce inflammation and the activation of immune cells, thereby achieving the effect of treating inflammatory and autoimmune diseases. Compared to the marketed drug Upadacitinib, VC005 has lower JAK2 inhibitory activity based on in vitro kinase assay results, which may help alleviate a series of safety issues caused by excessive JAK2 inhibition in the clinic. VC005 has been developed as oral tablets which demonstrated positive top-line results in treating moderate to severe atopic dermatitis in clinical studies. Currently, the drug is in Phase III stage of its development for the treatment of Moderate to Severe Atopic Dermatitis.

TQH2722: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

TQH2722 is a humanized monoclonal antibody developed by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., specifically targeting the interleukin 4 receptor alpha (IL4Rα). This innovative therapeutic agent achieves dual-blockade of interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling, effectively inhibiting the T-helper cell type 2 (Th2) immune pathway. By targeting this inflammatory mechanism, TQH2722 aims to provide a promising treatment approach for moderate to severe atopic dermatitis, with early clinical trials demonstrating a well-tolerated safety profile and potential for managing Th2-mediated inflammatory conditions. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Moderate to Severe Atopic Dermatitis.

Rezpegaldesleukin: Nektar Therapeutics

REZPEG (NKTR-358) is a novel first-in-class regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions. Research suggests that suboptimal levels of Treg cells, powerful inhibitory immune cells, and lack of Treg cell activity may underlie the development of autoimmune and inflammatory diseases, including lupus and psoriasis. REZPEG (NKTR-358) works by targeting the IL-2 receptor complex and preferentially stimulating the proliferation of Treg cells without stimulating cytotoxic CD8+ T and CD4+ T cells, which drive autoimmune disease. Activation of Tregs suppresses disease-causing T cells and restores the body’s self-tolerance mechanisms. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Moderate to Severe Atopic Dermatitis.

QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

QY201 tablets are a new generation of highly active JAK1/TYK2 dual-target inhibitors independently developed by Enitiate Biologicals, and are highly selective for JAK2. By blocking the JAK-STAT pathway through inhibition of JAK activity, QY201 reduces the expression of pro-inflammatory cytokines, thereby exerting therapeutic effects on autoimmune diseases such as atopic dermatitis and psoriasis. QY201 inhibits both JAK1 and TYK2 with high selectivity and activity, signaling that the risk of toxicity due to QY201 inhibition of other kinase targets is low. QY201 tablets can rapidly stop itching, clear skin lesions, and improve the quality of life of patients with moderate-to-severe atopic dermatitis. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Moderate to Severe Atopic Dermatitis.

Soquelitinib: Corvus Pharmaceuticals, Inc.

Soquelitinib is an innovative investigational small molecule drug developed by Corvus Pharmaceuticals, designed to selectively inhibit interleukin-2-inducible T cell kinase (ITK). This novel therapeutic agent targets the complex immunological mechanisms underlying atopic dermatitis by modulating T cell differentiation and immune response. Specifically, Soquelitinib works by inducing the generation of Th1 helper cells while simultaneously blocking the development of Th2 and Th17 cells, which are critically involved in the pathogenesis of inflammatory and allergic conditions. By strategically inhibiting specific molecular targets in T cells, soquelitinib offers a potential breakthrough in managing moderate to severe atopic dermatitis through its unique immunomodulatory approach. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Moderate to Severe Atopic Dermatitis.

Moderate to Severe Atopic Dermatitis: Therapeutic Assessment

This segment of the report provides insights about the different Moderate to Severe Atopic Dermatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Moderate to Severe Atopic Dermatitis

• There are approx. 45+ key companies which are developing the therapies for Moderate to Severe Atopic Dermatitis. The companies which have their Moderate to Severe Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu vcare pharmaceutical technology co., LTD.

Phases

The report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Moderate to Severe Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Moderate to Severe Atopic Dermatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Moderate to Severe Atopic Dermatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate to Severe Atopic Dermatitis drugs.

Moderate to Severe Atopic Dermatitis Report Insights

• Moderate to Severe Atopic Dermatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Moderate to Severe Atopic Dermatitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Moderate to Severe Atopic Dermatitis drugs?
• How many Moderate to Severe Atopic Dermatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate to Severe Atopic Dermatitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Moderate to Severe Atopic Dermatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Moderate to Severe Atopic Dermatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jiangsu vcare pharmaceutical technology co., LTD
• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Nektar Therapeutics

• E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Corvus Pharmaceuticals, Inc.

UCB Biopharma SRL

• Tavotek Biotherapeutics
• Guangdong Hengrui Pharmaceutical Co., Ltd
• SCM Lifescience Co., LTD.

Sanofi

• Amgen
• Qurient Co., Ltd.

Sun Pharmaceutical Industries Limited

• Pfizer
• UNION therapeutics
• Bio-Thera Solutions
• medac GmbH
• Eli Lilly and Company
• AbbVie
• Lynk Pharmaceuticals Co., Ltd
• LEO Pharma
• Guangzhou JOYO Pharma Co., Ltd
• Beijing InnoCare Pharma Tech Co., Ltd.

Oneness Biotech Co., Ltd.

Evommune, Inc.

Key Products

• VC005
• TQH2722
• Rezpegaldesleukin
• QY201
• Soquelitinib
• UCB9741
• TAVO101
• SHR-1819
• SCM-AGH
• SAR444656
• Rocatinlimab
• Q301
• SCD-044
• PF-07832837
• Orismilast
• BAT6026
• Methotrexate
• LY3454738
• Lutikizumab
• LNK01001
• LEO 138559
• JYP0061
• ICP-332
• FB825
• EVO301

This product will be delivered within 1-3 business days.